A biochemical breakthrough using simple carbon atoms, by Ken Yamada, Ph.D., and Anastasia Khvorova, Ph.D., has dramatically improved the stability and efficacy of a potential oligonucleotide ...

Although the concept of using synthetic oligonucleotides to modulate RNA function was described as early as 1978, 1 its realization in the form of drugs approved by the Food and Drug Administration ...

Nanocarriers enhance peptide and oligonucleotide therapy by improving stability, bioavailability, and targeted delivery for effective clinical applications.

As the importance and prevalence of oligonucleotide therapeutics continue to grow, so does the need for robust characterization methodologies throughout drug development and production. Given the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company’s launch and $100 million in initial ...

Modern medicine depends on large, information-rich molecules such as peptides and oligonucleotides. These molecules carry biological instructions that can be directed toward specific disease pathways.

Nucleic-acid-based drugs have attracted significant funding and development by pharmaceutical and biotech companies in recent years, as researchers aim to harness their ability to halt the production ...

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...

The oligonucleotides market offers opportunities in therapeutic applications, particularly for untreated diseases using ASOs, siRNA, and aptamers, with leaders like Alnylam driving innovation. Growth ...

Currently approved oligonucleotide drugs induce cleavage of a target mRNA or alter the splicing pattern. Cleavage-inducing oligonucleotides have structural and chemical features that recruit ...